

## INVESTMENT APPROACH

Combining OneAscent's values-based investing approach and Eventide's portfolio management insight, the strategy is actively managed and invested in equities of healthcare companies that are primarily within the biotechnology industry.

The strategy invests primarily in U.S. equities, with foreign exposure typically less than 10%. The size-weighted, average market cap range is typically \$1-15 billion USD.

Stock selection is driven by Eventide's fundamental research and values-based criteria. Investment decisions may also take into account overall market conditions and trading volumes.

This strategy may be appropriate for investors seeking high absolute returns with

## INVESTMENT PROCESS

- **Identify companies** with (1) strong fundamentals, (2) that create value for stakeholders, and (3) trade at attractive valuations.
- **Establish an investment case** based on fundamental analysis of the company's products or services, the industry in which it operates, sustainable competitive advantages, management team, and financials as well as research on how the company creates value for patients, doctors, the healthcare system, employees, society, the environment, and local communities. Valuation analysis is then performed to establish a price target as well as upside and downside valuation.
- **Evaluate the health of the market** by utilizing a three-legged stool approach to assess leading indicators, valuation measures, and investor sentiment.
- **Construct the portfolio** with appropriate industry and sector weightings informed by the level of macro risk. Determine position sizing based on conviction level and risk/reward profile.
- **Actively monitor holdings** to ensure that the investment thesis remains intact.

## INVESTMENT OBJECTIVE

Long-term capital appreciation

## TARGET HOLDINGS

40-70

## BENCHMARK

NASDAQ Biotechnology Index

## INVESTMENT MINIMUM

\$50,000

## MANAGEMENT FEE

0.70%

## MANAGED BY



Finny Kuruvilla serves as Chief Investment Officer and Portfolio Manager for Eventide Asset Management. Dr. Kuruvilla has a unique background in healthcare, statistics, and investing.

Eventide Asset Management is an independently registered third party investment adviser and is not affiliated with OneAscent Investment Solutions.



## TRAILING RETURNS


Inception Date: 3/29/2017

	YTD	1 Year	3 Years	5 Years	Since Inception
OneAscent Healthcare	23.31	23.33	-8.56	7.00	6.87
NASDAQ Biotechnology TR USD	4.59	4.60	-2.03	8.26	5.99

OneAscent Investment Solutions LLC ("OneAscent") was formed in March 2017, and manages a variety of equity, income and balanced asset strategies for client accounts. OneAscent is an investment adviser registered with the United States Securities and Exchange Commission. Registration as an investment adviser does not imply any certain degree of skill or training. OneAscent's Form ADV Part 2A is available on its website, [www.oneascent.com](http://www.oneascent.com), or the SEC's website, at [www.adviserinfo.sec.gov](http://www.adviserinfo.sec.gov), or by contacting the firm. Please consult OneAscent's Form ADV Part 2A for information regarding account minimums and fees.

Performance information for the attached strategy is calculated using model performance and is based on the portfolio allocation data since inception. The strategy has not materially changed since inception. Model performance is net of any fees on underlying mutual funds and ETFs and a management fee of 0.70% applied annually to the entire strategy. The model performance does not include any overlay fees, brokerage fees, or commissions. OneAscent is unaware of what the exact amounts of these fees will be on a client by client basis, and cannot reasonably estimate their costs. Performance for periods longer than a year has been annualized. Model performance means that while actual client accounts will be managed as closely to the model as possible, the performance reported is for the targeted portfolio allocations for the strategy and not a composite of actual client accounts. Accordingly, individual client performance may vary according to various factors, including fee arrangements, withdrawals, contributions, and tax considerations, among other factors. The above stated portfolio performance is gross of any third party financial advisor's fees. A client's returns will be reduced by the advisory fee if incurred in the management of its account. For example, the deduction of a 1% advisory fee over a 10-year period would reduce a 10% gross return to an 8.9% net return. OneAscent does not control the fee amounts charged by recommending advisers. A complete listing of all trades in the model, as well as a full description of the model/strategy are available upon request.

## SECTOR ALLOCATION



## TOP HOLDINGS

Company	Ticker	Weight %
Karuna Therapeutics Inc	KRTX	5.91
Zentalis Pharmaceuticals Inc Ordinary Shares	ZNTL	3.83
Celldex Therapeutics Inc	CLDX	3.63
Exact Sciences Corp	EXAS	3.62
908 Devices Inc Ordinary Shares	MASS	3.18
IDEXX Laboratories Inc	IDXX	3.12
Blueprint Medicines Corp	BPMC	3.01
Cytokinetics Inc	CYTK	2.92
Marinus Pharmaceuticals Inc	MRNS	2.52
Mirum Pharmaceuticals Inc	MIRM	2.51

## MARKET RISK

	Std Dev	Alpha	Beta	R2	Sharpe
OneAscent Healthcare	30.10	0.02	1.17	60.37	0.31
NASDAQ Biotechnology TR USD	20.03	0.00	1.00	100.00	0.39

## ANNUAL RETURNS

	2017*	2019	2020	2021	2022	2023
OneAscent Healthcare	21.35	44.09	27.24	-19.54	-22.96	23.33
NASDAQ Biotechnology TR USD	9.30	25.13	26.36	0.02	-10.13	4.60

The benchmark used for this strategy is the NASDAQ Biotechnology Total Return Index. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index. Indices are reported to give a point of comparison only. An investor may not invest directly in an index. Benchmark data is provided by Morningstar and has not been independently verified.

The strategy is not necessarily appropriate for any particular client or investor. Accordingly, any reader of the attached description should not interpret the attached as investment advice. All investments bear a risk of loss, including the loss of principal that the investor should be prepared to bear. The use of any chart or graph in the attached is not intended to be viewed as a singular aid in determining investment strategy. Such visual aids are instead intended as a complement to other data, and like such other data, should be considered in light of consultations with professional investment tax and legal advisors. Past performance may not be indicative of future results. No current or prospective client should assume that the future performance of any specific investment, investment strategy (including investments and/or investment strategies recommended by the adviser), will be equal to past performance levels. Indices are reported to give a point of comparison only. An investor may not invest directly in an index. Different types of investments involve varying degrees of risk, and there can be no assurance that any specific investment will either be suitable or profitable for a client's investment portfolio.

\*Partial period return (April 1, 2017 to December 31, 2017).